Find uplifting stories about heroes, innovations, and solutions
71 results for "hepatitis"
New World Health Organization data shows hepatitis C deaths have fallen 12% globally since 2015, with childhood hepatitis B infections down to just 0.6%. Countries like Egypt, Georgia, and Rwanda are proving that eliminating this deadly disease is possible with the right commitment and tools.
A medication already being tested for hepatitis C shows promising results against hepatitis E, a deadly virus that kills 70,000 people yearly and has no approved treatment. Scientists discovered bemnifosbuvir stops the virus from replicating without harming healthy cells.
A groundbreaking hepatitis B treatment has achieved what was once thought impossible: completely clearing the virus from patients' bodies. One in five participants in recent trials are now virus-free, offering hope to 296 million people worldwide living with chronic hepatitis B.
After years without any approved therapies, adults living with chronic hepatitis delta virus now have hope with the FDA's approval of Hepcludex, the first treatment for one of the most severe forms of viral hepatitis. This breakthrough fills a critical gap for nearly 200,000 Americans who face rapid progression to serious liver complications.
A groundbreaking hepatitis D treatment just won approval in China, offering hope to 12 million people worldwide living with one of the most severe forms of viral hepatitis. The drug represents a rare full-journey innovation, from basic science discovery to market-ready medicine, all developed domestically.
A new treatment for one of the deadliest forms of viral hepatitis just got approved in China, offering hope to 12 million people worldwide who had almost no options. The drug, developed entirely in China from discovery to delivery, blocks both hepatitis B and D viruses from entering liver cells.
A simple fingerstick test for hepatitis B is just as accurate as traditional lab testing, and delivers results in 60 minutes instead of days. This breakthrough could save lives by bringing testing to remote communities where 254 million people worldwide need better access to care.
A team of researchers across five countries just received $24 million to find a cure for hepatitis B, a virus that affects 300 million people worldwide. The five-year effort could finally bring hope to millions living with a disease that currently has no cure.
Researchers at UC San Francisco discovered how certain immune cells can cure chronic hepatitis B infections, solving a 15-year medical mystery. The breakthrough could help hundreds of millions of people worldwide beat a virus that kills over a million annually.
A breakthrough medication called bepirovirsen has functionally cured 20% of chronic hepatitis B patients within one year, marking the first major treatment advance in decades. The FDA is expected to decide on approval this October.
Australian researchers proved a simple fingerstick test detects hepatitis B as accurately as lab tests, delivering results in just one hour instead of weeks. The breakthrough could bring lifesaving treatment to 254 million people worldwide who lack access to testing.
A team of scientists across five countries just received $24 million to pursue something 300 million people are waiting for: a cure for hepatitis B. The five-year project brings together researchers from Brazil, India, Senegal, Uganda, and the United States to turn laboratory discoveries into real treatments.
A groundbreaking treatment has achieved functional cures in one-fifth of chronic hepatitis B patients, offering hope for a disease that affects 296 million people worldwide. The weekly injection made the virus undetectable even after treatment stopped.
A groundbreaking hepatitis B treatment is helping one in five patients stop therapy entirely while keeping the deadly liver virus undetectable. After decades of searching, researchers may have found the path to a functional cure for a disease that kills 1.1 million people yearly.
For the first time, a new treatment called bepirovirsen has achieved functional cure in 1 in 5 hepatitis B patients, compared to nearly zero with current therapies. This breakthrough could free millions from lifelong daily medication.
An experimental treatment by GSK achieved functional cures for nearly 20% of hepatitis B patients in major clinical trials, a massive leap from the 1-3% success rate of current medications. The breakthrough offers hope for millions living with a virus that kills a million people annually.
A groundbreaking hepatitis B treatment is letting patients stop therapy while keeping the deadly liver virus undetectable. The experimental drug achieved a "functional cure" in 20% of trial participants, a breakthrough decades in the making.
A new drug has functionally cured chronic hepatitis B in one in five patients, offering hope for the 254 million people living with the world's most common liver infection. The FDA is expected to decide on approval by October 2026.
An experimental medicine called bepirovirsen achieved functional cures in nearly 20% of chronic hepatitis B patients during clinical trials, a massive leap from current treatments that cure only 1% to 3%. For a disease killing 1 million people annually, this breakthrough could transform millions of lives.
A groundbreaking combination therapy has left nearly 9 in 10 hepatitis D patients with no detectable virus after two years of treatment. The results could transform care for a disease that often leads to liver failure within five years.
Showing 20 of 71